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Human papillomavirus: a strong case for vaccinating boys 
 
GILLIAN PRUE 
 
Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
worldwide, so predominant and so easily acquired that nearly all sexually active men and 
women will be exposed to the virus at some point in their lives. The rate of genital HPV 
infection is similar in males and females; however males have a lower immune response to 
natural HPV infection than their female counterparts,1 meaning that there is not the same 
association between age and HPV prevalence in men as there is in women. In women, HPV 
prevalence peaks between 18–24 years and subsequently declines.2. In contrast, in men, there 
is a consistently higher prevalence of HPV.3 
 
There many different types of HPV, and varying degrees of risk associated with persistent 
infection with each type. Many HPV infections are short-lived and clinically insignificant, 
but continual infection with certain types of HPV causes a considerable burden of disease in 
both sexes. Cervical cancer has been unequivocally linked to persistent infection with HPV,4 
with two high-risk types, HPV 16 and 18, being linked to 70% of the cases of cervical cancer 
worldwide.5 In addition to cervical cancer, HPV has been linked to other cancers and non-
cancerous conditions in both men and women, for example genital warts, oropharyngeal 
cancer (OPC), anal cancer or penile cancer. Estimates of the incidence of HPV-related 
cancers for 2008 has been calculated globally; of the estimated 12.7 million cancers, 610 000 
could be attributed to HPV infection.6 According to Stanley, in Europe around 23 250 cases 
of cervical cancer each year plus vaginal and vulval cancer (3,850 cases), several head and 
neck (15 230 cases) as well as anal cancers (4630 cases) in both sexes and penile cancer 
(1090 cases) can be attributed to HPV.7 HPV also causes 614 700 cases of genital warts. In 
Europe, in men specifically, each year, there are an estimated 15 490 new cases of HPV-
related cancer in men and 325 700 new cases of genital warts. 
 
Successful HPV vaccination in females in combination with adequate screening programmes 
has made remarkable progress in the reduction and prevention of cervical cancer; less 
progress has been made with other HPV-related cancers affecting both sexes. In the USA, it 
has been predicted that soon the number of HPV-related OPCs diagnosed in a year will 
surpass the annual number of cervical cancer cases.8 Anal cancer incidence has increased 
rapidly over the past 30 years in the UK in both sexes. Men-who-have-sex-with-men (MSM) 
carry a disproportionate burden of anal cancer, similar to cervical cancer rates in females 
before the introduction of screening, and there is an increased incidence of anal cancer 
amongst MSM in comparison to heterosexual male population (over 15:1). Furthermore, 
HIV-positive MSM have an up to 80-fold estimated higher risk than HIV-negative men or 
women of developing anal cancer.  
 
EFFECTIVE VACCINES 
Two HPV vaccines are now licensed for use in many countries; a bivalent vaccine which 
protects against two high-risk types of HPV (HPV 16/18) and a quadrivalent vaccine 
protecting against the two high-risk HPV types and two low-risk types associated with genital 
warts (HPV 6/11/16/18). A new nonavalent vaccine has been developed to cover nine 
different types of HPV. In addition to HPV 6,11,16 and 18, it also includes protection against 
HPV 31,33,45,52 and 58. 
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HPV vaccines have been shown to be effective in men. In a study of 4065 males aged 16–26 
years old, the quadrivalent HPV vaccine was shown to be effective in preventing genital 
warts, penile cancer and anal cancer.1,9 In addition, a meta-analysis of 29 studies (8360 men) 
that reported on HPV vaccine acceptability found a moderate level of acceptability in men,10 
indicating that men would have the HPV vaccine if it was offered.  
 
THE CASE FOR VACCINATING BOYS 
Despite HPV’s impact on the health of both sexes and the availability of an effective vaccine 
for both adolescent males and females, Australia, Austria, Canada, Israel, Switzerland and 
USA recommend the vaccination of boys. Within country, HPV vaccination for boys is now 
also recommended in the German region of Saxony and the Italian regions of Emilia-
Romagna and Sicily. Emilia-Romagna has recently introduced a vaccination program for 
HIV-positive males under 26.Countries offering female only vaccination believe males will 
be protected from HPV-related illness as a result of herd protection ie a reduction in the risk 
of infection in males due to reduced exposure as a result of female vaccination.11 It is true 
that a high coverage in females may promote this herd protection, and there is some 
developing evidence that this is the case. An analysis of high-uptake female only vaccination 
programmes in nine countries found a reduction of around one third in the number of boys 
with genital warts.12 However, even if herd protection is achieved with high female 
vaccination uptake, men are not protected as soon as they move outside of the ‘herd’. Men 
will live and work in other countries where females are not vaccinated and as a result likely 
become infected with HPV.  
 
Female-only vaccination strategies do provide some degree of protection for men who have 
sex with women within the herd, but they offer no protection for MSM. Due to the higher 
incidence of anal cancer and the current lack of protection for MSM, the Joint Commission 
for Vaccinations and Immunisations (JCVI) in the UK announced in November 2015 that the 
current UK female only vaccination policy be extended to MSM aged up to 45 years via a 
genitourinary medicine (GUM) or Human Immunodeficiency Virus (HIV) clinic, or 
opportunistic vaccination via GPs. Superficially this may seem to be a suitable cost-effective 
answer, but a targeted MSM HPV vaccination programme would be difficult to implement. 
The vaccine offers most protection if it is given to the person before exposure to HPV. It is 
totally inappropriate, impractical and unethical to ask adolescent boys if they are likely to 
have sex with another male when they are older, and if so, would they consider HPV 
vaccination. The proposed solution suggested by the JCVI will most likely not protect the 
majority of MSM. Most MSM are likely to have had multiple sexual partners with increased 
risk of HPV acquisition before they attend a sexual health clinic.13 Also, many gay and 
bisexual men do not attend GUM clinics. There are also MSM who do not identify as gay or 
homosexual and will not disclose their sexual activity to a healthcare professional, meaning 
they will never be offered the vaccination. In addition, offering HPV vaccination to MSM up 
to the age of 45 if introduced would present a further inequality, as women in the UK are not 
currently offered vaccination up to this age. 
 
QUESTIONS OF COST-EFFECTIVENESS 
 
Cost-effectiveness of a male vaccination programme is influenced by the degree of uptake of 
the vaccine in females. With a low uptake in girls, the cost-effectiveness of vaccinating boys 
is more easily demonstrated. The potential impact of a male vaccination programme has been 
estimated via various mathematical models, and a debate currently exists around their cost-
effectiveness. Many models do not support the inclusion of men, but frequently MSM are not 
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included in the model, and the focus is largely on the impact of the vaccine in terms of 
cervical cancer outcome and not predicting the impact on other HPV related cancers.14  
 
A recent study provided a comprehensive health and economic assessment supporting the 
direct benefit of vaccinating boys along with girls against oncogenic HPV in the 
Netherlands.15 The analysis demonstrated that with a 60% uptake in females the burden of 
vaccine-preventable cancers in men reduced by approximately one third, with a 90% uptake 
in females, the burden of HPV related cancers in men was reduced by 66%; however anal 
cancer decreased by only one third. It was concluded that this was owing to the 
disproportionate burden of anal cancer in MSM and who do not benefit from female only 
vaccination strategies. It was concluded that the incremental benefit of including boys in 
vaccination programmes was driven by the prevention of anal cancer. This validates the 
importance of including MSM in cost-effectiveness modelling. The burden of genital warts is 
comparable to the burden of HPV-related cancers; the Dutch study did not assess the impact 
on genital warts, which could have led to an under-estimation of the impact of a universal 
vaccination strategy.  The study is complemented by another recent cost-effectiveness 
analysis of male HPV vaccination in Canada, which suggested that HPV vaccination of 
adolescent boys may be a cost-effective strategy for the prevention of OPC.16 
 
HUMAN COST 
The human cost of HPV related diseases should be the primary consideration for including 
boys in HPV vaccination programmes. HPV-related lower genital tract lesions and genital 
warts significantly impair psychosocial wellbeing and health-related quality of life.17 Patients 
with head and neck cancer experience profound visible, functional and psychological 
consequences from their disease and treatment. A decision on whether or not to vaccinate 
boys should not solely be made on the basis of cost-effectiveness - the psychosocial impacts 
of HPV-related disease must be considered when calculating the benefit of male HPV 
vaccination.  
 
Withholding a vaccine from any group of individuals at risk of developing that vaccine-
preventable disease is unethical. It is also unfair for females to be expected to carry the 
responsibility for HPV prevention through vaccination, particularly when HPV is a virus that 
is sexually transmitted, and affects both sexes so prolifically. The burden of HPV-related 
diseases is now almost the same in men as in women. Unlike cervical cancer, there are no 
reliable and cost-effective screening methods to prevent cancers caused by HPV among men. 
A gender-neutral vaccination programme would achieve real herd immunity; without male 
vaccination men who move outside of the herd, and especially MSM, remain at risk of HPV 
infection and life-threatening and life-altering HPV related diseases.  
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